Skip to main content

Table 1 Overall incidence and prevalence rates of MPS in United States (1995–2015) based on the National MPS Society membership

From: Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities

MPS type

Number of patients

Percentage of all MPS (%)

Incidence per 100,000

Prevalence per 1,000,000

MPS I (Hurler Syndrome)

207

26.23

0.26

0.70

MPS II (Hunter Syndrome)

207

26.23

0.26

0.70

MPS III (Sanfilippo Syndrome)

210

26.60

0.26

0.71

 Type A

153

19.40

0.19

0.52

 Type B

40

5.10

0.05

0.14

 Type C

12

1.50

0.015

0.04

 Type D

0

0.00

0

0

MPS IV (Morquio Syndrome)

113

14.32

0.14

0.38

 Type Aa

87

11.00

0.11

0.29

 Type B

3

0.40

0.004

0.01

MPS VI (Maroteaux-Lamy Syndrome)

31

3.92

0.04

0.11

MPS VIIb (Sly Syndrome)

21

2.70

0.027

0.07

MPS IX (Hyaluronidase deficiency)

0

0.00

0

0

All Mucopolysaccharidoses

789

100.00

0.98

2.67

  1. Some patients are reported as MPS III or IV while there is no information on the sub-type
  2. aBased on information from the MPS IVA International registry [7]
  3. bBased on information provided by Ultragenyx Pharmaceuticals